Riskpilot← Back to searchSign inGet full accessAbarceo Pharma AB
ABActiveOrg 5591397160Per Albin Hanssons Väg 41Research and experimental development on natural sciences and engineering · NACE 7210Est. 20175 employees
Revenue 2024
SEK 4,9M
EBITDA margin
-136.1%
+60% vs 2023
Equity ratio
-313.2%
Financial strength
Net profit 2024
SEK -6,8M
+59% vs 2023
| Revenue | SEK 4,9M | — |
| EBITDA | SEK -6,7M | +60% |
| Net profit | SEK -6,8M | +59% |
| Total assets | SEK 5,9M | +22% |
| Equity | SEK -18,6M | -57% |
| Employees | 5 | — |
Legal name
Abarceo Pharma AB
Org number
5591397160
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14 december 2017
Share capital
SEK 108 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva läkemedelsutveckling samt därmed förenlig verksamhet.
Address
Per Albin Hanssons Väg 41
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 4 889 |
| Staff expenses | — | — | — | — | — | — | — |
| EBITDA | −298 | −1 127 | −1 174 | −8 899 | −15 521 | −16 441 | −6 656 |
| Depreciation & amort. | −0 | −0 | −0 | −7 221 | −66 | −98 | −98 |
| EBIT | −298 | −1 127 | −1 174 | −16 120 | −15 587 | −16 539 | −6 754 |
| Net financials | — | — | −2 | −2 | −1 | 43 | 1 |
| Profit before tax | −298 | −1 127 | −1 176 | −16 122 | −15 588 | −16 496 | −6 754 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −298 | −1 127 | −1 176 | −16 122 | −15 588 | −16 496 | −6 754 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 1 385 | 6 299 | 8 164 | 12 987 | 17 106 | 4 888 | 5 948 |
| Equity | 1 156 | 6 064 | 4 907 | 10 909 | −4 624 | −11 878 | −18 631 |
| Long-term debt | 0 | 0 | 1 600 | 0 | 14 172 | 10 423 | 0 |
| Short-term debt | 229 | 236 | 1 656 | 2 077 | 7 558 | 6 343 | 24 580 |
| Total debt | 229 | 236 | 3 256 | 2 077 | 21 730 | 16 766 | 24 580 |
EBITDA margin
-136.1%
This company
15.8%
Market median
-961% vs market
20182024
Equity ratio
-313.2%
This company
38.2%
Market median
-920% vs market
20182024
Return on equity
-675400000.0%
This company
18.4%
Market median
-3670652274% vs market
20182024
Net profit margin
-138.1%
This company
8.1%
Market median
-1805% vs market
20182024
Asset turnover
0.82×
This company
1.12×
Market median
+27% vs market
20182024
Debt / equity
1.32×
This company
0.62×
Market median
-113% vs market
20182024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-12-01 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JA Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
KJ Chief Auditor | Chief Auditor | 2020 | — | — |
KA Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
ÅC Chief Auditor | Chief Auditor | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2025 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Abarceo Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Adam Patrik Bruce | Chief Executive Officer | 0 companies |
| Karin Jeanette Roosberg | Chief Auditor | 0 companies |
| Kristian Arne Adolfsen | Chief Executive Officer | 0 companies |
| Åsa Cecilia Andersson Eneberg | Chief Auditor | 0 companies |
| Siegfried Ulrich Koch | Board of Directors | 0 companies |
| Tara Renée Heitner Hansen | Board of Directors | 0 companies |
| Per Gunnar Ernst Aniansson | Chairman | 0 companies |
| Annie George Chandy | Chairman | 0 companies |
| Mathias Kroll | Board of Directors | 0 companies |
| Tara Heitner Hansen | Board of Directors | 0 companies |
| Milan Zdravkovic | Board of Directors | 0 companies |
| Claes Wollheim | Board of Directors | 0 companies |
| Helen Monika Pettersson | Board of Directors | 0 companies |
| Claes Tomas Post | Board of Directors | 0 companies |
| Sebastian Albert Ali Salehi | Board of Directors | 0 companies |